See more : Asmo Corporation (2654.T) Income Statement Analysis – Financial Results
Complete financial analysis of Oncorus, Inc. (ONCR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Oncorus, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Bangkok Life Assurance Public Company Limited (BLA.BK) Income Statement Analysis – Financial Results
- Jinhui Shipping and Transportation Limited (JIN.OL) Income Statement Analysis – Financial Results
- China Energy Engineering Corporation Limited (601868.SS) Income Statement Analysis – Financial Results
- International Zeolite Corp. (IZCFF) Income Statement Analysis – Financial Results
- Gold Fields Limited (GFI) Income Statement Analysis – Financial Results
Oncorus, Inc. (ONCR)
About Oncorus, Inc.
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 54.74M | 44.68M | 27.15M | 24.05M | 12.54M |
| General & Administrative | 21.79M | 20.14M | 10.00M | 7.12M | 6.04M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 21.79M | 20.14M | 10.00M | 7.12M | 6.04M |
| Other Expenses | 0.00 | -9.00K | -11.29M | -47.00K | 304.00K |
| Operating Expenses | 76.54M | 64.82M | 37.15M | 31.17M | 18.58M |
| Cost & Expenses | 76.54M | 64.82M | 37.15M | 31.17M | 18.58M |
| Interest Income | 911.00K | 65.00K | 143.00K | 509.00K | 228.00K |
| Interest Expense | 2.01M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.12M | 1.95M | 1.37M | 1.07M | 956.00K |
| EBITDA | -75.42M | -62.87M | -37.15M | -30.10M | -17.62M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -76.54M | -64.82M | -37.15M | -31.17M | -18.58M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -885.00K | 56.00K | -11.15M | 462.00K | 532.00K |
| Income Before Tax | -77.42M | -64.76M | -48.30M | -30.70M | -18.05M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 885.00K | -65.00K | -1.52M | -509.00K | 532.00K |
| Net Income | -78.31M | -64.70M | -46.78M | -30.20M | -18.05M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.02 | -2.56 | -7.69 | -2.42 | -1.97 |
| EPS Diluted | -3.02 | -2.56 | -7.69 | -2.42 | -1.97 |
| Weighted Avg Shares Out | 25.92M | 25.32M | 6.08M | 12.50M | 9.16M |
| Weighted Avg Shares Out (Dil) | 25.92M | 25.32M | 6.08M | 12.50M | 9.16M |
Why Is Oncorus (ONCR) Stock Down 27% Today?
Oncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat
Oncorus to Participate in Upcoming Investor Conferences
Oncorus, Inc. (ONCR) Moves to Buy: Rationale Behind the Upgrade
Oncorus to Present at Chardan's 6th Annual Genetic Medicines Conference
Oncorus to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Here's Why Oncorus, Inc. (ONCR) Looks Ripe for Bottom Fishing
Oncorus to Present at the Jefferies Global Healthcare Conference
Oncorus to Present at the H.C. Wainwright Global Investment Conference
Oncorus to Present at the Maxim Group 2022 Virtual Growth Conference
Source: https://incomestatements.info
Category: Stock Reports